mk 0663 has been researched along with Stevens-Johnson Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devkota, R; Dhungel, A; Dongol, A; Pandey, A; Parajuli, S | 1 |
| Hélou, J; Maatouk, I; Moutran, R | 1 |
| Bramsiepe, I; Eismann, R; Kreft, B; Marsch, WC; Winkler, M; Wohlrab, J | 1 |
| Boshier, A; Friedmann, P; Layton, D; Marshall, V; Shakir, SA | 1 |
4 other study(ies) available for mk 0663 and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Etoricoxib Induced Toxic Epidermal Necrolysis in a case of Systemic Lupus Erythematosus: A Case Report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Etoricoxib; Exanthema; Female; Humans; Lupus Erythematosus, Systemic; Stevens-Johnson Syndrome | 2022 |
Etoricoxib-induced toxic epidermal necrolysis.
Topics: Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Low Back Pain; Male; Middle Aged; Pyridines; Stevens-Johnson Syndrome; Sulfones | 2014 |
Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab.
Topics: Adult; Antibodies, Monoclonal; Cyclooxygenase 2 Inhibitors; Dermatologic Agents; Etoricoxib; Humans; Infliximab; Male; Pyridines; Stevens-Johnson Syndrome; Sulfones; Treatment Outcome | 2010 |
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; England; Etoricoxib; Female; Humans; Incidence; Lactones; Male; Middle Aged; Pyrazoles; Pyridines; Research Design; Retrospective Studies; Skin; Stevens-Johnson Syndrome; Sulfonamides; Sulfones; Surveys and Questionnaires | 2006 |